Join us Thursday 4/24 at 2pm Central Time, as we focus on the valuation range for Ford (F). Register here. HIDE

Gilead Sciences (GILD)

Add to Watchlists
Create an Alert
73.29 -0.57  -0.77% NASDAQ Apr 24, 11:13AM BATS Real time Currency in USD
View Full Chart
GILD Price Chart
View All Events

GILD Events

Date Type Description
Apr 22 Earnings Gilead Sciences Inc Q1 2014 Earnings Results. Estimate: 0.75.
Apr 22 Misc Gilead Sciences Inc Q1 2014 Earnings Conference Call
Feb 04 Misc Fourth Quarter 2013 Gilead Sciences Earnings Conference Call
Feb 04 Earnings Fourth Quarter 2013 Gilead Sciences Earnings Results. Estimate: 0.49.
Oct 29 Misc Third Quarter 2013 Gilead Sciences Earnings Conference Call - See More At:
Oct 29 Earnings Third Quarter 2013 Gilead Sciences Earnings. Estimate: 0.49.
Jul 25 Misc Second Quarter 2013 Gilead Sciences Earnings Conference Call - See More At:
Jul 25 Earnings Gilead Sciences to Release Second Quarter 2013 Financial Results on Thursday, July 25, 2013. Estimate: 0.46.
May 02 Misc Gilead Sciences Inc 2013 First Quarter Earnings Conference Call
May 02 Earnings First Quarter 2013 Financial Results. Estimate: 0.47.
View All Performance Charts

GILD Total Returns Comparison

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Gilead Sciences is up 37.43% over the last year vs S&P 500 Total Return up 21.66%, Amgen up 2.36%, and Pfizer up 1.52%.

Get Quote for

PDF Report for GILD

Download Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.

Download GILD Pro Report PDF

Portfolio Strategies Featuring GILD

Did Gilead Sciences make it into our Portfolio Strategies?
Start your YCharts membership now to find out.

GILD Profile

  • Sector: Healthcare
  • Industry: Biotechnology
  • Headquarters Country: United States
  • Headquarters State/Province: California
  • Incorporation Country: United States
  • Incorporation State/Province: Delaware
  • Est. Current Fiscal Quarter End: June 30, 2014
  • Est. Current Fiscal Year End: December 31, 2014
  • Last Fiscal Quarter End: March 31, 2014
  • Last Fiscal Year End: December 31, 2013
  • NAICS: Biological Product (except Diagnostic) Manufacturing
  • NAICS Code: 325414
  • NAICS Industry: Pharmaceutical and Medicine Manufacturing
  • NAICS Industry Code: 3254
  • NAICS Sector: Manufacturing
  • NAICS Sector Code: 32

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Gilead has operations in North America, Europe and Asia Pacific. The Company focuses on the development and commercialization of human therapeutics for life threatening diseases. The Company’s products include Truvada, Atripla, Viread, Emtriva, Hepsera, AmBisome, Letairis, Ranexa, Vistide and Cayston. Its products are marketed through its commercial teams and/or in conjunction with third-party distributors and corporate partners. The Company has United States and international commercial sales operations, with marketing subsidiaries in Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, the Netherlands, New Zealand, Norway, Poland, Portugal, Spain, Sweden, Switzerland, Turkey, the United Kingdom and the United States. On July 8, 2010, the Company acquired CGI Pharmaceuticals, Inc. (CGI). The company was founded in 1987 and is headquartered in Foster City, California.

Recent Quotes

Symbol Price Chg Chg % Market Cap
GILD 73.29 -0.57 -0.77% 112.74B
Create Watchlist from Quotes

Already registered? Click here to sign in.

Access watchlists and custom data alerts.
Start your free account.

Get Started Now

Upgrade to {{}}. Start Your YCharts Membership. Start your {{}} Membership


{{ ? "Upgrade Now" : "Get Started Now"}}

Already a YCharts Member? Already a {{}} Member? Sign in here.